Skip to content

    Gland Pharma

    GLANDGood
    Healthcare·20 May 2025
    Management Summary

    Gland Pharma reported a quarter of mixed results, characterized by a flat full-year revenue performance but significant strategic progress in high-growth areas like GLP-1s and Biologics. While the base business remains highly profitable with 38% EBITDA margins, the Cenexi acquisition continues to be a drag on consolidated performance, though management expects an EBITDA-positive turnaround by Q3 FY26. The company is aggressively expanding its cartridge capacity to 140 million units to capture the burgeoning GLP-1 market.

    Highlights

    8

    • Consolidated Revenue for Q4 FY25 stood at ₹1,424.9 crores, showing sequential improvement over Q3.

    • Consolidated EBITDA margin expanded to 24%, a 100bps increase year-over-year.

    • Base business (excluding Cenexi) reported a healthy EBITDA margin of 38% for the quarter.

    • Net Profit (PAT) for Q4 increased by 3% YoY to ₹186.5 crores.

    • Successful entry into the GLP-1 segment with the launch of liraglutide and two secured contracts.

    • US market top 10 molecules grew by 26% in volume, despite pricing adjustments due to lower material costs.

    • Cenexi gross margin improved to 79% from 77% in the prior quarter, despite operational challenges at the Fontenay facility.

    • Net cash position remains strong at ₹2,287 crores as of March 31, 2025.

    Concerns

    1

    • US Reciprocal Tariffs

    What Changed2

    vs Q1 FY26

    Guidance items5 → 6 (+1)Risks discussed4 → 3 (-1)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹1,424.9 Cr+10%QoQ
    2. 02EBITDA Margin24%
    3. 03PAT₹186.5 Cr+3%YoY
    4. 04R&D Spend₹50.3 Cr+15%YoY
    5. 05Net Cash₹2,287 Cr

    Segment breakdown

    Base Business (Ex-Cenexi)
    ₹1,033.2 Cr Revenue38% EBITDA Margin-12% YoY Growth
    Cenexi
    43 Mn Revenue79% Gross Margin
    List

    Guidance & targets

    6
    CategoryTargetPriority
    Revenue
    Consolidated Revenue Growth
    15%
    		High
    Revenue
    US Revenue Growth
    18%
    		High
    Revenue
    Biologics Revenue
    ₹100 crores
    		High
    Revenue
    Cenexi Revenue Target
    €300 million
    		Medium
    Capacity
    Cartridge Capacity
    140 million units
    		High
    Profitability
    Cenexi EBITDA Breakeven
    Positive
    		Medium

    Risks & concerns

    5
    RiskSeverity

    US Reciprocal Tariffs

    Management notes a layer of uncertainty for Indian pharma companies due to potential US administration tariff announcements. — Both acknowledged

    high

    Cenexi Operational Disruptions

    Ongoing remediation at Fontenay and equipment breakdowns impacted Q4 performance and shipments. — Management acknowledged

    medium

    ROW Tender Misses

    Delays in Saudi NUPCO contract due to tech transfer for local manufacturing of Enoxaparin. — Management acknowledged

    medium

    Areas of Evasion(2)

    • Specific order book details for Cenexi (asked for time to come back).
    • Exact number of first-to-file exclusivity ANDAs (deferred to provide later).

    Q&A highlights

    3

    “Is this a business even worth pursuing based on whatever obviously benefits of hindsight and whatever your understanding is currently? Is it a business worth pursuing?”

    Analysts are openly questioning the strategic value of the Cenexi acquisition given the high cost and slow turnaround.

    asked by Dheeresh Pathak, WhiteOak

    2 min read5 chapters

    Detailed Narrative

    01

    GLP-1 Segment Becomes a Strategic Pillar

    Gland Pharma has successfully entered the GLP-1 market with the launch of liraglutide and secured two major contracts. To meet anticipated demand, the company is aggressively scaling its cartridge capacity from 40 million to 140 million units by CY 2026. Management expects this segment to be a significant volume driver, with fill-finish pricing estimated between $1 to $2 per unit.

    02

    Cenexi Turnaround and High-Value Shift

    The Cenexi subsidiary remains a work in progress, with management shifting focus from low-value, high-volume business (previously 70% of operations) to high-value products like pre-filled syringes and lyophilized vials. Despite remediation challenges at the Fontenay site, gross margins improved to 79%. The company targets EBITDA breakeven for Cenexi by Q3 FY26 and €300 million in revenue within three years.

    03

    US Market Resilience Amid Pricing Pressure

    The US business saw a 26% volume growth in its top 10 molecules during Q4. While revenue growth was tempered by lower transfer prices (driven by reduced material costs), margins remained intact. Management is targeting 18% growth in the US for FY26, supported by 31 new product launches in FY25 and a robust pipeline of RTU infusion bags and complex injectables.

    04

    Biologics CDMO Entry Gains Momentum

    Gland is building a robust CDMO setup for biologics, with a key collaboration with Dr. Reddy's Laboratories expected to contribute revenue starting in FY26. The company is expanding its bioreactor capacity by 15,000 liters and expects the biologics segment to generate approximately ₹100 crores in revenue in the next fiscal year, marking a significant step into the biosimilars market.

    05

    ROW and Emerging Markets Expansion

    Despite a 14% decrease in ROW revenue in Q4 due to tender misses and tech transfers in Saudi Arabia, Gland maintains a long-term vision to double this business over the next 3-5 years. The company has over 500 registrations pending in high-growth emerging markets and is leveraging its approved US/India portfolio to deepen its global reach.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.